Ben Taylor, Ph.D., M.Sc.

Ben Taylor is a pharmacoepidemiologist. He received his PhD in epidemiology and biostatistics from the University of Toronto and has over 12 years of experience leading RWE strategy and execution for products across therapeutic areas and development cycles. Before joining Aetion, he worked for Amgen Inc. for more than eight years, leading cross-functional RWE generation and strategy in the cardiovascular franchise for both pipeline and marketed products. He then spent two years building a consulting practice inside a small health technology company, guiding the use of RWE from Phase 2/3 planning through launch and post-marketing surveillance across therapeutic areas for the top 20 global pharmaceutical manufacturers.

Currently, as VP of Science at Aetion, he leads integrated evidence generation planning for both large and small biotechnology companies, and leads a number of COVID-19-related and oncology-focused regulatory-facing workstreams, including creating new standards in the use of RWE and ECAs in regulatory decision making comparative safety and effectiveness analyses in the U.S. and globally.